Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
|Videos|December 12, 2019
The IMpassion130 trial in Metastatic Triple-Negative Breast Cancer
Author(s)Rita Nanda, MD
Rita Nanda, MD, discusses the IMpower130 trial in patients with metastatic triple-negative breast cancer who express PD-L1.
Advertisement
Rita Nanda, MD, associate professor of medicine and director of the Breast Oncology Program at The University of Chicago, discusses the IMpassion130 trial in patients with metastatic triple-negative breast cancer (TNBC) who express PD-L1.
The IMpassion130 trial has been practice-changing for Nanda and many other providers, creating a new standard of care for women with metastatic TNBC whose cancer expresses the PD-L1 protein. Pembrolizumab is not yet approved in the neoadjuvant setting, but Nanda is hopeful it will come.
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5